SCHEMBL19783461

SCHEMBL19783461

Cc1c(O)cc2sc(Br)nc2c1Cl

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NSD1 Q96L73 1/20 0.37
HTT P42858 2/20 0.36
MAPT P10636 2/20 0.31
LMNA P02545 1/20 0.31
PRNP P04156 1/20 0.31
HPGD P15428 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
NOD2 Q9HC29 1/20 0.31
ACHE P22303 1/20 0.30
GPR35 Q9HC97 1/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
KMT2A Q03164 1/20 0.30
GAA P10253 2/20 0.30
MGAM O43451 1/20 0.30
SI P14410 1/20 0.30
MGAM2 Q2M2H8 1/20 0.30
NQO2 P16083 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19782967 0.84 HTT (0.42) NSD1HTTMAPTLMNAPRNP
SCHEMBL19782755 0.79 NSD1 (0.37) NSD1LMNAGAAMGAMSI
SCHEMBL19782781 0.77 MAPT (0.38) MAPTPRNPNPSR1MEN1KMT2A
SCHEMBL19783063 0.76 NSD1 (0.37) NSD1HTTLMNAPRNPHPGD
SCHEMBL21395812 0.73
SCHEMBL19783026 0.73 PDE10A (0.32) KMT2A
SCHEMBL19783689 0.70 LMNA (0.45) HTTLMNAHPGDNPSR1MEN1
SCHEMBL21395798 0.70 MAPT (0.34) MAPTGPR35NPC1KMT2AGAA
SCHEMBL19782753 0.69 HSD17B10 (0.42) NSD1HTTMAPTMEN1NPC1
SCHEMBL19783180 0.69 ALDH1A1 (0.42) NSD1MAPTLMNAMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 CN disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 NSD1 3520/4885HTT 2480/4885MAPT 1432/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 NSD1 3382/4885HTT 2559/4885MAPT 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.